ArriVent BioPharma, Inc.

AVBPdata completeness 63%3 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'totalDebt'; no data for concept 'interestExpense'; no data for concept 'incomeTaxExpense'; no data for concept 'pretaxIncome'

The thesis, from the filings

ArriVent BioPharma, Inc. earns about -43% on equity, but has diluted owners by 1697% over 3 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2023	FY 2024	FY 2025
Revenue	—	—	—
Net income	−$69.3M¹	−$80.5M²	−$166.3M²
Operating cash flow	−$55.8M³	−$70.2M⁴	−$160.6M⁴
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	—	—	—
Cash & equivalents	$150.4M⁵	$74.3M⁶	$45.5M⁶
Diluted shares	2.1M	31.5M	38.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$79.88

your share of equity

Profit it earned you last year

−$43.24

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on $79.88 of net worth that earned you −$43.24 last year.

iii. Is this a good business?

Moat signal · return on equity

-43% avg · 3y

FY23 —FY24 -31%FY25 -54%

It earned an average -43% on equity over 3 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+1697% shares · 3y

Share count is up 1697% over 3 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2023-12-31 · accession 0001558370-25-001999 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001104659-26-024127 (NetIncomeLoss)
10-K · period ending 2023-12-31 · accession 0001558370-25-001999 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001104659-26-024127 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001558370-25-001999 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2024-12-31 · accession 0001104659-26-024127 (CashAndCashEquivalentsAtCarryingValue)